S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Eton Pharmaceuticals Stock Forecast, Price & News

+0.03 (+0.82%)
(As of 12/3/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
378,967 shs
Average Volume
498,736 shs
Market Capitalization
$91.30 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ETON News and Ratings via Email

Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Eton Pharmaceuticals logo

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.


Eton Pharmaceuticals Reports Third Quarter Financial Results
November 15, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$40 thousand
Book Value
$0.64 per share


Net Income
$-27.97 million
Pretax Margin




Free Float
Market Cap
$91.30 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.12 out of 5 stars

Medical Sector

483rd out of 1,390 stocks

Pharmaceutical Preparations Industry

220th out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -

Eton Pharmaceuticals (NASDAQ:ETON) Frequently Asked Questions

Is Eton Pharmaceuticals a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Eton Pharmaceuticals stock.
View analyst ratings for Eton Pharmaceuticals
or view top-rated stocks.

How has Eton Pharmaceuticals' stock been impacted by COVID-19?

Eton Pharmaceuticals' stock was trading at $4.20 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ETON shares have decreased by 11.7% and is now trading at $3.71.
View which stocks have been most impacted by COVID-19

Are investors shorting Eton Pharmaceuticals?

Eton Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 720,000 shares, an increase of 36.0% from the October 31st total of 529,400 shares. Based on an average daily trading volume, of 345,500 shares, the short-interest ratio is presently 2.1 days. Approximately 3.6% of the shares of the stock are sold short.
View Eton Pharmaceuticals' Short Interest

When is Eton Pharmaceuticals' next earnings date?

Eton Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 15th 2022.
View our earnings forecast for Eton Pharmaceuticals

How were Eton Pharmaceuticals' earnings last quarter?

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) released its earnings results on Monday, November, 15th. The company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.10. Eton Pharmaceuticals had a negative trailing twelve-month return on equity of 58.04% and a negative net margin of 67.52%. During the same period in the previous year, the company earned ($0.31) EPS.
View Eton Pharmaceuticals' earnings history

What price target have analysts set for ETON?

2 analysts have issued twelve-month target prices for Eton Pharmaceuticals' stock. Their forecasts range from $11.00 to $14.00. On average, they anticipate Eton Pharmaceuticals' stock price to reach $12.50 in the next year. This suggests a possible upside of 236.9% from the stock's current price.
View analysts' price targets for Eton Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Eton Pharmaceuticals' key executives?

Eton Pharmaceuticals' management team includes the following people:
  • Sean E. Brynjelsen, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Wilson W. Troutman, Chief Financial Officer, Secretary & Treasurer
  • Scott Grossenbach, Vice President-Sales & Marketing
  • Ingrid Hoos, Senior Vice President-Scientific Affairs
  • Paul Stickler, Senior Vice President-Sales & Marketing

What other stocks do shareholders of Eton Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eton Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Myovant Sciences (MYOV), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC) and Moderna (MRNA).

When did Eton Pharmaceuticals IPO?

(ETON) raised $22 million in an IPO on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation served as the underwriter for the IPO.

What is Eton Pharmaceuticals' stock symbol?

Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol "ETON."

Who are Eton Pharmaceuticals' major shareholders?

Eton Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Opaleye Management Inc. (12.55%), Westside Investment Management Inc. (0.43%), GSA Capital Partners LLP (0.33%), Bank of New York Mellon Corp (0.32%), Morgan Stanley (0.14%) and Citadel Advisors LLC (0.00%). Company insiders that own Eton Pharmaceuticals stock include Harrow Health, Inc, Opaleye Management Inc, Pharmaceutical Co Ltd Takeda and Sean Brynjelsen.
View institutional ownership trends for Eton Pharmaceuticals

Which major investors are selling Eton Pharmaceuticals stock?

ETON stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Millennium Management LLC, and Citadel Advisors LLC. Company insiders that have sold Eton Pharmaceuticals company stock in the last year include Harrow Health, Inc, Opaleye Management Inc, and Pharmaceutical Co Ltd Takeda.
View insider buying and selling activity for Eton Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Eton Pharmaceuticals stock?

ETON stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Morgan Stanley, GSA Capital Partners LLP, Belvedere Trading LLC, Goldman Sachs Group Inc., Two Sigma Investments LP, CHICAGO TRUST Co NA, and HighVista Strategies LLC. Company insiders that have bought Eton Pharmaceuticals stock in the last two years include Opaleye Management Inc, and Sean Brynjelsen.
View insider buying and selling activity for Eton Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Eton Pharmaceuticals?

Shares of ETON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eton Pharmaceuticals' stock price today?

One share of ETON stock can currently be purchased for approximately $3.71.

How much money does Eton Pharmaceuticals make?

Eton Pharmaceuticals has a market capitalization of $91.30 million and generates $40 thousand in revenue each year. The company earns $-27.97 million in net income (profit) each year or ($0.45) on an earnings per share basis.

How many employees does Eton Pharmaceuticals have?

Eton Pharmaceuticals employs 16 workers across the globe.

What is Eton Pharmaceuticals' official website?

The official website for Eton Pharmaceuticals is www.etonpharma.com.

Where are Eton Pharmaceuticals' headquarters?

Eton Pharmaceuticals is headquartered at 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010.

How can I contact Eton Pharmaceuticals?

Eton Pharmaceuticals' mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The company can be reached via phone at (847) 787-7361 or via email at [email protected].

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.